Page last updated: 2024-08-17

ethyl methanesulfonate and nelfinavir

ethyl methanesulfonate has been researched along with nelfinavir in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (93.33)	29.6817
2010's	1 (6.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonnet, PA; Civade, C; Gimeno, P; Levaillant, D; Maggio, AF; Rebiere, H; Tissier, MH	1
Wilcox, RD	1
Gocke, E; Müller, L; Pfister, T	1
Eichinger-Chapelon, A; Pfister, T	1
Gocke, E; Lavé, T; Müller, L; Pfister, T	1
Birnböck, H; Götschi, A; Lavé, T; Pähler, A; Ramp, T	1
Gocke, E; Grimm, HP; Lavé, T; Müller, L; Paehler, A	1
Lutz, WK	1
Müller, L; Singer, T	1
Gerber, C; Toelle, HG	1
Bürgin, H; Gocke, E; Müller, L; Pfister, T	1
Gocke, E; Wall, M	1
Casciano, DA; Tweats, DJ; Walker, VE	1
Blanche, S; Goujon, S; Hleyhel, M; Sibiude, J; Warszawski, J	1

Reviews

1 review(s) available for ethyl methanesulfonate and nelfinavir

Article	Year
Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; DNA; DNA Damage; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; HIV Protease Inhibitors; Humans; Male; Mice; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests	2009

Article

Year

Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3

Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; DNA; DNA Damage; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; HIV Protease Inhibitors; Humans; Male; Mice; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests

2009

Other Studies

14 other study(ies) available for ethyl methanesulfonate and nelfinavir

Article	Year
Viracept recommended for reinstatement in Europe. AIDS patient care and STDs, 2007, Volume: 21, Issue:10 Topics: Anti-HIV Agents; Drug Contamination; Ethyl Methanesulfonate; Europe; Licensure; Nelfinavir	2007
Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry. Pharmeuropa scientific notes, 2008, Volume: 2008, Issue:1 Topics: Calibration; Ethyl Methanesulfonate; Gas Chromatography-Mass Spectrometry; Nelfinavir; Reproducibility of Results; Tablets	2008
Changes are recommended in use of nelfinavir. HIV clinician, 2008,Winter, Volume: 20, Issue:1 Topics: Drug Contamination; Drug Industry; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Nelfinavir	2008
EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; Carcinogenicity Tests; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; Genes, Dominant; Genes, Lethal; Germ-Line Mutation; HIV Protease Inhibitors; Humans; Linear Models; Mammary Neoplasms, Animal; Methyl Methanesulfonate; Mice; Mutagenicity Tests; Nelfinavir; No-Observed-Adverse-Effect Level; Pregnancy; Quantitative Structure-Activity Relationship; Rats; Risk Assessment	2009
General 4-week toxicity study with EMS in the rat. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drug Contamination; Eating; Ethyl Methanesulfonate; Female; Genitalia; Hematologic Tests; Hemoglobins; HIV Protease Inhibitors; Male; Mutagens; Nelfinavir; Organ Size; Rats; Rats, Wistar; Risk Assessment; Specific Pathogen-Free Organisms; Toxicity Tests	2009
Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Dose-Response Relationship, Drug; Drug Contamination; Environmental Exposure; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Mice; Mutagens; Mutation; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests	2009
In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Half-Life; Hemoglobins; HIV Protease Inhibitors; Humans; Macaca fascicularis; Male; Mice; Microsomes, Liver; Mutagens; Nelfinavir; Rats; Risk Assessment; Species Specificity; Tablets; Valine	2009
Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Area Under Curve; Computer Simulation; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Hemoglobins; HIV Protease Inhibitors; Humans; In Vitro Techniques; Macaca fascicularis; Mice; Microsomes, Liver; Models, Biological; Mutagens; Nelfinavir; Rats; Risk Assessment; Species Specificity; Valine	2009
The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination? Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Animals; Dose-Response Relationship, Drug; Drug Contamination; Environmental Exposure; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Mice; Mutagenicity Tests; Mutagens; Nelfinavir; No-Observed-Adverse-Effect Level; Product Surveillance, Postmarketing; Rats; Risk Assessment	2009
EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Adult; Animals; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drug Contamination; Drug-Related Side Effects and Adverse Reactions; Ethyl Methanesulfonate; European Union; Female; History, 21st Century; HIV Protease Inhibitors; Humans; Mice; Mutagenicity Tests; Mutagens; Nelfinavir; No-Observed-Adverse-Effect Level; Pregnancy; Product Surveillance, Postmarketing; Rats; Registries; Risk Assessment	2009
What happened: the chemistry side of the incident with EMS contamination in Viracept tablets. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Dose-Response Relationship, Drug; Drug Contamination; Environmental Exposure; Ethyl Methanesulfonate; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Humans; Mutagens; Nelfinavir; Product Surveillance, Postmarketing; Tablets	2009
In vivo genotoxicity of EMS: statistical assessment of the dose response curves. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Confidence Intervals; DNA; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Lac Operon; Linear Models; Mice; Micronuclei, Chromosome-Defective; Mutagenicity Tests; Mutagens; Mutation; Nelfinavir; No-Observed-Adverse-Effect Level; Risk Assessment	2009
The Viracept-EMS case: impact and outlook. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Dose-Response Relationship, Drug; Drug Contamination; Environmental Exposure; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Mice; Mutagenicity Tests; Mutagens; Mutation; Nelfinavir; No-Observed-Adverse-Effect Level; Product Surveillance, Postmarketing; Rats; Risk Assessment	2009
In-utero exposure to nelfinavir-ethyl methyl sulfone. AIDS (London, England), 2016, 11-13, Volume: 30, Issue:17 Topics: Adolescent; Child; Child, Preschool; Congenital Abnormalities; Drug Contamination; Ethyl Methanesulfonate; Female; Follow-Up Studies; France; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal Exchange; Mutagens; Nelfinavir; Pregnancy; Prenatal Exposure Delayed Effects; Prospective Studies	2016